CN109414435A - 使用哌苯甲醇治疗行为综合征的方法 - Google Patents

使用哌苯甲醇治疗行为综合征的方法 Download PDF

Info

Publication number
CN109414435A
CN109414435A CN201780032282.5A CN201780032282A CN109414435A CN 109414435 A CN109414435 A CN 109414435A CN 201780032282 A CN201780032282 A CN 201780032282A CN 109414435 A CN109414435 A CN 109414435A
Authority
CN
China
Prior art keywords
meratran
pharmaceutically acceptable
treatment
acceptable salt
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780032282.5A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN109414435A publication Critical patent/CN109414435A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201780032282.5A 2016-05-26 2017-05-25 使用哌苯甲醇治疗行为综合征的方法 Pending CN109414435A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341855P 2016-05-26 2016-05-26
US62/341,855 2016-05-26
PCT/US2017/034443 WO2017205606A1 (en) 2016-05-26 2017-05-25 Methods of treating behavioral syndromes using pipradrol

Publications (1)

Publication Number Publication Date
CN109414435A true CN109414435A (zh) 2019-03-01

Family

ID=60408578

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780032282.5A Pending CN109414435A (zh) 2016-05-26 2017-05-25 使用哌苯甲醇治疗行为综合征的方法

Country Status (10)

Country Link
US (3) US9827233B1 (https=)
EP (1) EP3439657A4 (https=)
JP (1) JP2019517469A (https=)
KR (1) KR20190013737A (https=)
CN (1) CN109414435A (https=)
AU (1) AU2017268795A1 (https=)
CA (1) CA3025473A1 (https=)
IL (1) IL262986A (https=)
MX (1) MX2018013973A (https=)
WO (1) WO2017205606A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
KR20190013737A (ko) * 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들
CN111328282A (zh) * 2017-09-12 2020-06-23 奥维德医疗公司 加波沙朵在治疗发作性睡病中的用途
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
EP3880201A4 (en) 2018-12-17 2022-07-27 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF NON-24 HOUR SLEEP waking disorder
GB201911056D0 (en) * 2019-08-02 2019-09-18 Sanchez Hector Mario Treatment of ADD/ADHD
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024030A1 (en) * 1995-12-29 1997-07-10 Guilford Pharmaceuticals Inc. Pyrrolidine derivatives
WO2008095253A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
CN103608004A (zh) * 2011-03-23 2014-02-26 艾伦索尔医药发展股份有限公司 用于治疗注意力缺陷障碍的方法和组合物
US20160058746A1 (en) * 2008-11-03 2016-03-03 Durect Corporation Oral Pharmaceutical Dosage Forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US8865746B2 (en) 2008-07-18 2014-10-21 Zafgen, Inc. Methods of treating an overweight or obese subject
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
EP2575853B1 (en) 2010-05-25 2016-08-24 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
KR20190013737A (ko) * 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024030A1 (en) * 1995-12-29 1997-07-10 Guilford Pharmaceuticals Inc. Pyrrolidine derivatives
WO2008095253A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20160058746A1 (en) * 2008-11-03 2016-03-03 Durect Corporation Oral Pharmaceutical Dosage Forms
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
CN103608004A (zh) * 2011-03-23 2014-02-26 艾伦索尔医药发展股份有限公司 用于治疗注意力缺陷障碍的方法和组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. COPPOLAAET AL.: "Research chemicals marketed as legal highs: The case of pipradrol derivatives", 《TOXICOLOGY LETTERS》 *
师海波等: "《最新临床药物手册 第3版》", 31 January 2013, 军事医学科学出版社 *

Also Published As

Publication number Publication date
KR20190013737A (ko) 2019-02-11
WO2017205606A1 (en) 2017-11-30
US20170340619A1 (en) 2017-11-30
CA3025473A1 (en) 2017-11-30
JP2019517469A (ja) 2019-06-24
EP3439657A1 (en) 2019-02-13
EP3439657A4 (en) 2019-12-18
IL262986A (en) 2018-12-31
US10493069B2 (en) 2019-12-03
US9827233B1 (en) 2017-11-28
US20190076415A1 (en) 2019-03-14
AU2017268795A1 (en) 2018-11-22
US20180036298A1 (en) 2018-02-08
MX2018013973A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
CN109414435A (zh) 使用哌苯甲醇治疗行为综合征的方法
Zhu et al. Risks associated with misuse of ketamine as a rapid-acting antidepressant
Malykh et al. Piracetam and piracetam-like drugs
EP2029130B1 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
TWI326214B (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
CA3138008A1 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
TWI553006B (zh) 依託拉嗪(eltoprazine)於治療與神經或心理疾病有關之認知失能之症狀的用途
HK1255132A1 (zh) 使用哌苯甲醇治疗发育障碍的方法
US20220023316A1 (en) Methods for the treatment of depression
JP2023505155A (ja) 神経変性疾患に関連する認知障害を治療する方法
US20120046302A1 (en) Methods of treating cns disorders
TWI831896B (zh) 用於治療多巴胺性cns病症之ly3154207劑量療法
US20240197756A1 (en) Methods of treatment with neuroactive steroids
US20230285345A1 (en) Combination methods and compositions including sleep therapeutics for treating mood
Silva et al. Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder
Mahmoud et al. Tramadol as an analgesic
Zare et al. Wake-Promoting agents; insights into clinical use and molecular perspectives
AU2024204318A1 (en) Treatment of Post-Traumatic Syndrome Disorder
Chabukswar et al. A REVIEW ON APPLICATIONS OF DEXMEDETOMIDINE (BXCL501) IN CNS DISORDERS
HK40003594A (en) Methods of treating behavioral syndromes using pipradrol
Soroka et al. Ketamine in affective disorders–expectations and limitations
WO2023243659A1 (ja) 線条体ストリオソームのドパミンｄ１シグナルを標的とした強迫性障害の薬物療法
Aronoff et al. Adjuvant Analgesics in Neuropathic Pain
Mishkan Dextromethorphan, an NMDA receptor antagonist, as a treatment for pain
Keogh et al. Recent Advances in the Pharmacological Management of Neuropathic Pain

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40003594

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20190301

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40003594

Country of ref document: HK